JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sardi, S. P.
Right arrow Articles by Rothlin, R. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sardi, S. P.
Right arrow Articles by Rothlin, R. P.

Vol. 290, Issue 3, 1019-1025, September 1999

Further Pharmacological Characterization of Bradykinin B1 Receptor Up-Regulation in Human Umbilical Vein1

Sergio Pablo Sardi, Federico Manuel Daray, Andrea Emilse Errasti, Facundo Germán Pelorosso, Virginia Andrea Pujol-Lereis, Verónica Rey-Ares, María Pía Rogines-Velo and Rodolfo Pedro Rothlin

Departamento de Farmacología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina

Previous reports have provided evidence to support the view that the de novo synthesis of bradykinin (BK) B1 receptor is involved in the induction of vascular responses in human umbilical vein (HUV). In the present study, we evaluated different pharmacological tools to further analyze this up-regulation process in HUV. Concentration-response curves to des-Arg9-BK, a selective BK B1 receptor agonist, were performed after 5 h of incubation. Tumor necrosis factor-alpha potentiated BK B1 receptor responses at 5 h without modifying the maximal response to des-Arg9-BK. Pyrrolidine dithiocarbamate, an inhibitor of nuclear factor-kappa B activation, produced a concentration-dependent decrease of the BK B1 receptor sensitization. When tissues were continuously exposed to actinomycin D, a transcription inhibitor, or cycloheximide, a protein synthesis inhibitor, concentration-response curves to des-Arg9-BK were markedly diminished. On the other hand, transitory exposure to cycloheximide allowed the full recovery of BK B1 receptor-sensitized responses at 5 h. Finally, continuous incubation with the N-linked glycosylation inhibitor, tunicamycin, almost completely abolished des-Arg9-BK-mediated responses. In summary, this sensitization process is potentiated by tumor necrosis factor-alpha and is selectively inhibited by pyrrolidine dithiocarbamate, suggesting that BK B1 receptor up-regulation in HUV involves nuclear factor-kappa B activation. The effects of actinomycin D and tunicamycin provide evidence that the de novo synthesis of a transmembrane glycoprotein has an obligatory role in the BK B1 up-regulation. The reversion of the cycloheximide effect on BK B1 response indicates that the time necessary for synthesis, trafficking, and functional membrane expression of this receptor would be less than 1 h.

0022-3565/99/2903-1019$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
F. G. Pelorosso, A. V. Halperin, A. M. Palma, W. Nowak, A. E. Errasti, and R. P. Rothlin
Neutral Endopeptidase Up-Regulation in Isolated Human Umbilical Artery: Involvement in Desensitization of Bradykinin-Induced Vasoconstrictor Effects
J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 713 - 720.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
A. Prat, K. Biernacki, T. Saroli, J. E. Orav, C. R. G. Guttmann, H. L. Weiner, S. J. Khoury, and J. P. Antel
Kinin B1 Receptor Expression on Multiple Sclerosis Mononuclear Cells: Correlation With Magnetic Resonance Imaging T2-Weighted Lesion Volume and Clinical Disability
Arch Neurol, May 1, 2005; 62(5): 795 - 800.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
L. M. F. Leeb-Lundberg, F. Marceau, W. Muller-Esterl, D. J. Pettibone, and B. L. Zuraw
International Union of Pharmacology. XLV. Classification of the Kinin Receptor Family: from Molecular Mechanisms to Pathophysiological Consequences
Pharmacol. Rev., March 1, 2005; 57(1): 27 - 77.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
R. Medeiros, D. A. Cabrini, J. Ferreira, E. S. Fernandes, M. A.S. Mori, J. B. Pesquero, M. Bader, M. C.W. Avellar, M. M. Campos, and J. B. Calixto
Bradykinin B1 Receptor Expression Induced by Tissue Damage in the Rat Portal Vein: A Critical Role for Mitogen-Activated Protein Kinase and Nuclear Factor-{kappa}B Signaling Pathways
Circ. Res., May 28, 2004; 94(10): 1375 - 1382.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. P. Sardi, V. Rey-Ares, V. A. Pujol-Lereis, S. A. Serrano, and R. P. Rothlin
Further Pharmacological Evidence of Nuclear Factor-kappa B Pathway Involvement in Bradykinin B1 Receptor-Sensitized Responses in Human Umbilical Vein
J. Pharmacol. Exp. Ther., June 1, 2002; 301(3): 975 - 980.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. Houle, M. Landry, R. Audet, J. Bouthillier, D. R. Bachvarov, and F. Marceau
Effect of Allelic Polymorphism of the B1 and B2 Receptor Genes on the Contractile Responses of the Human Umbilical Vein to Kinins
J. Pharmacol. Exp. Ther., July 1, 2000; 294(1): 45 - 51.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.